Examining the association of habitual e-cigarette use with inflammation and endothelial dysfunction in young adults: The VAPORS-Endothelial function study.
e-cigarette
endothelial dysfunction
flow-mediated dilation
inflammation
reactive hyperemia index
Journal
Tobacco induced diseases
ISSN: 1617-9625
Titre abrégé: Tob Induc Dis
Pays: Greece
ID NLM: 101201591
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
01
2023
revised:
15
03
2023
accepted:
18
03
2023
medline:
12
6
2023
pubmed:
12
6
2023
entrez:
12
6
2023
Statut:
epublish
Résumé
Acute exposure to e-cigarette aerosol has been shown to have potentially deleterious effects on the cardiovascular system. However, the cardiovascular effects of habitual e-cigarette use have not been fully elucidated. Therefore, we aimed to assess the association of habitual e-cigarette use with endothelial dysfunction and inflammation - subclinical markers known to be associated with increased cardiovascular risk. In this cross-sectional study, we analyzed data from 46 participants (23 exclusive e-cigarette users; 23 non-users) enrolled in the VAPORS-Endothelial function study. E-cigarette users had used e-cigarettes for ≥6 consecutive months. Non-users had used e-cigarettes <5 times and had a negative urine cotinine test (<30 ng/mL). Flow-mediated dilation (FMD) and reactive hyperemia index (RHI) were used to assess endothelial dysfunction, and we assayed high-sensitivity C-reactive protein, interleukin-6, fibrinogen, p-selectin, and myeloperoxidase as serum measures of inflammation. We used multivariable linear regression to assess the association of e-cigarette use with the markers of endothelial dysfunction and inflammation. Of the 46 participants with mean age of 24.3 ± 4.0 years, the majority were males (78%), non-Hispanic (89%), and White (59%). Among non-users, 6 had cotinine levels <10 ng/mL while 17 had levels 10-30 ng/mL. Conversely, among e-cigarette users, the majority (14 of 23) had cotinine ≥500 ng/mL. At baseline, the systolic blood pressure was higher among e-cigarette users than non-users (p=0.011). The mean FMD was slightly lower among e-cigarette users (6.32%) compared to non-users (6.53%). However, in the adjusted analysis, current e-cigarette users did not differ significantly from non-users in their mean FMD (Coefficient=2.05; 95% CI: -2.52-6.63) or RHI (Coefficient= -0.20; 95% CI: -0.88-0.49). Similarly, the levels of inflammatory markers were generally low and did not differ between e-cigarette users and non-users. Our findings suggest that e-cigarette use may not be significantly associated with endothelial dysfunction and systemic inflammation in relatively young and healthy individuals. Longer term studies with larger sample sizes are needed to validate these findings.
Identifiants
pubmed: 37305426
doi: 10.18332/tid/162327
pii: 75
pmc: PMC10257221
doi:
Types de publication
Journal Article
Langues
eng
Pagination
75Subventions
Organisme : NIEHS NIH HHS
ID : P30 ES030283
Pays : United States
Informations de copyright
© 2023 Boakye E. et al.
Déclaration de conflit d'intérêts
The authors have each completed and submitted an ICMJE form for disclosure of potential conflicts of interest. The authors declare that they have no competing interests, financial or otherwise, related to the current work. E. Boakye, O. El-Shahawy, J. Erhabor, A. Bhatnagar, and M. Blaha report that since the initial planning of the work this study was supported by Awards P50HL120163 and U54HL120163 from National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) and the FDA Center for Tobacco Products (CTP). S.S. Biswal reports that since the initial planning of the work this study was supported by R01 grant DE026031 from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH).
Références
J Am Heart Assoc. 2020 May 5;9(9):e014570
pubmed: 32345096
J Am Heart Assoc. 2017 Aug 30;6(9):
pubmed: 28855171
Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10
pubmed: 15173056
N Engl J Med. 1997 Apr 3;336(14):973-9
pubmed: 9077376
BMC Public Health. 2020 Oct 09;20(1):1518
pubmed: 33032554
Atherosclerosis. 2016 Dec;255:179-185
pubmed: 27693003
Int J Environ Res Public Health. 2022 Sep 07;19(18):
pubmed: 36141513
ERJ Open Res. 2019 Dec 23;5(4):
pubmed: 31886159
Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2113-9
pubmed: 17717291
JAMA Cardiol. 2017 Mar 1;2(3):278-284
pubmed: 28146259
Thorax. 2021 Jun;76(6):618-620
pubmed: 34157671
Circulation. 2009 Aug 11;120(6):502-9
pubmed: 19635967
Vasc Health Risk Manag. 2008;4(3):647-52
pubmed: 18827914
J Am Coll Cardiol. 2020 May 5;75(17):2271-2273
pubmed: 32354388
Am J Hypertens. 2004 Apr;17(4):314-20
pubmed: 15062884
Circulation. 2012 Aug 7;126(6):753-67
pubmed: 22869857
N Engl J Med. 2019 Oct 10;381(15):1490-1491
pubmed: 31532955
Arterioscler Thromb Vasc Biol. 2022 Nov;42(11):1333-1350
pubmed: 36288290
Circulation. 2007 May 8;115(18):2390-7
pubmed: 17452608
Chest. 2016 Sep;150(3):606-12
pubmed: 27108682
JAMA Netw Open. 2018 Dec 7;1(8):e185937
pubmed: 30646298
Tob Control. 2014 Mar;23(2):133-9
pubmed: 23467656
Am J Physiol Lung Cell Mol Physiol. 2019 Aug 1;317(2):L155-L166
pubmed: 31042077
MMWR Morb Mortal Wkly Rep. 2015 Apr 17;64(14):381-5
pubmed: 25879896
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):629-633
pubmed: 29879097
J Leukoc Biol. 2016 Nov;100(5):1105-1112
pubmed: 27312847
Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):29-38
pubmed: 15539615
Platelets. 2016 Nov;27(7):694-702
pubmed: 27096416
JAMA Netw Open. 2022 Jul 1;5(7):e2223266
pubmed: 35867060
Am J Physiol Heart Circ Physiol. 2022 Apr 1;322(4):H549-H567
pubmed: 35089811
MMWR Morb Mortal Wkly Rep. 2022 Oct 07;71(40):1283-1285
pubmed: 36201370
Vasc Med. 2018 Oct;23(5):419-425
pubmed: 29985113
Circulation. 2021 Feb 23;143(8):869-871
pubmed: 33390037
Cardiovasc Res. 2020 Jan 1;116(1):40-50
pubmed: 31696222